269 results
Page 2 of 14
8-K
EX-99.1
dqpbeo
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
0msh1gzyc2l9
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
EX-99.1
0tnxd1nyyki5 2nbdvtr
3 Aug 23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
4:20pm
8-K
EX-99.1
fguswh ijltrpblvr6
10 Jul 23
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
4:12pm
DEFA14A
oqy3glk1j 6sw9a2u
21 Jun 23
Additional proxy soliciting materials
5:18pm
8-K
EX-1.1
i2f9p3kwa3 yo
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.1
k5amp a3txg
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.2
4toon rv6
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
424B5
5dhkczf5ug1f2ema qk
8 Jun 23
Prospectus supplement for primary offering
4:17pm
424B5
qnloi1ip27x5 q7
6 Jun 23
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
4y1leyh531fghu
6 Jun 23
No Vaccine Related Serious Adverse Events (SAEs) reported to date
8:07am
8-K
EX-99.1
0rk7o
9 May 23
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
4:57pm
424B5
q8s5zfta7fnecl o5zg6
9 May 23
Prospectus supplement for primary offering
2:41pm